SCHEMBL3962061

SCHEMBL3962061

CN(C(=O)OC(C)(C)C)c1ccc2ccsc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAX8 Q06710 1/20 0.47
BRD4 O60885 2/20 0.40
CREBBP Q92793 1/20 0.34
OPRM1 P35372 1/20 0.33
OPRK1 P41145 1/20 0.33
MRGPRX4 Q96LA9 1/20 0.33
CSNK2A2 P19784 1/20 0.32
CSNK2B P67870 1/20 0.32
CSNK2A1 P68400 1/20 0.32
GBA1 P04062 1/20 0.32
RXRA P19793 1/20 0.31
NR1H2 P55055 1/20 0.31
NR1H3 Q13133 1/20 0.31
MT-CO2 P00403 1/20 0.31
CA12 O43570 1/20 0.31
CA2 P00918 1/20 0.31
PDE10A Q9Y233 1/20 0.31
MEN1 O00255 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15485751 0.89 PAX8 (0.47) PAX8BRD4CREBBPOPRM1OPRK1
SCHEMBL22671359 0.81 PAX8 (0.34) PAX8MRGPRX4MEN1RAB9AKMT2A
SCHEMBL29995765 0.81 PAX8 (0.34) PAX8MRGPRX4MEN1RAB9AKMT2A
SCHEMBL22671355 0.80 PAX8 (0.33) PAX8MRGPRX4
SCHEMBL25569912 0.77 CHRNA7 (0.34) PAX8OPRM1OPRK1MRGPRX4GBA1
SCHEMBL25569848 0.77 CHRNA7 (0.34) PAX8OPRM1OPRK1MRGPRX4GBA1
SCHEMBL25569913 0.77 CHRNA7 (0.34) PAX8OPRM1OPRK1MRGPRX4GBA1
SCHEMBL31453143 0.77 PAX8 (0.51) PAX8BRD4CREBBPMEN1RAB9A
SCHEMBL8018111 0.77 PAX8 (0.55) PAX8BRD4CREBBPRXRANR1H2
SCHEMBL16506622 0.76 PAX8 (0.48) PAX8BRD4PDE10AMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG PAX8 4755/4885BRD4 28/4885CREBBP 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.